

Date: 30th May, 2022

To
The Manager
Dept of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001
Scrip Code: 511 509

Dear Sir/Madam,

Subject : Outcome of Board Meeting
Scrip Code : 511509

With reference to the above cited subject, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, viz. Monday, 30th May, 2022, *inter-alia*, transacted the following business:

1. Approved Audited Standalone & Consolidated Financial Results for the fourth quarter and year ended 31st March, 2022.
2. Took note of the Auditor's Reports forming part of Audited Standalone and Consolidated Financial Results for the fourth quarter and year ended 31st March, 2022.

The meeting commenced at 08.00 p.m. and concluded at 09.15 p.m.

This is for your information and records.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited


Jyotika Aasat
Company Secretary



Vivo Bio Tech Ltd
8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate
Road No.1, Banjara Hills, Hyderabad-500034, Telangana
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

AUDITED STANDALONE FINANCIAL RESULTS FOR THE QTR AND YEAR ENDED 31ST MARCH, 2022

S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED		Rs. in Lacs
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021	
		Refer Note#2	Un-Audited	Refer Note#2	Audited	Audited	
I	Revenue from operations	1,530.54	1292.02	1,608.13	5,139.10	5177.52	
II	Other Income	(15.26)	0	7.87	9.21	7.87	
III	Total Income	1,515.28	1292.02	1615.99	5148.31	5185.38	
IV	Expenses						
	a) Increase/(decrease) in stock in trade and WIP	343.08	(12.27)	(342.47)	346.52	(269.86)	
	b) Consumption of Raw materials	-	0	-	-	-	
	c) Purchase of traded goods	299.28	132.65	510.80	797.28	990.56	
	d) Employees Cost	280.25	239.36	266.76	942.19	856.99	
	e) Depreciation and amortisation	220.49	171.03	175.33	744.08	559.14	
	f) Finance Cost	86.61	120.37	125.36	399.33	352.99	
	g)Administrative Expenditure	447.32	356.8	772.41	1,471.53	1833.38	
	Total	1677.02	1007.94	1508.20	4700.92	4323.20	
V	Profit Before Tax (III-IV)	(161.74)	284.08	107.79	447.39	862.18	
VI	Exceptional Item			0.00		0.00	
VII	Profit Before Tax	(161.74)	284.08	107.79	447.39	862.18	
	Tax Expense						
	a. Current Tax	(48.78)	43.76	(60.38)	75.35	135.76	
	b. Deferred tax	(45.03)	103.11	138.22	151.22	157.97	
	Total Tax Expense	(93.82)	146.87	77.85	227.06	293.74	
	Net Profit After Tax (V-VI)	(67.92)	137.21	29.95	220.33	568.44	
VIII	Other Comprehensive Income						
	a.items that will be reclassified to profit or loss (Net of Tax)		-	-		-	
IX	Total other Comprehensive Income(VII+VIII+IX)	(67.92)	137.21	29.95	220.33	568.44	
X	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1426.35	1420.45	1341.95	1426.35	1341.95	
XI	Earnings per equity share:						
	1)Basic	-0.48	0.97	0.22	1.56	4.24	
	2)Diluted	-0.48	0.93	0.22	1.56	4.20	

Place: Hyderabad
Date: 30th May, 2022

For Vivo Bio Tech Ltd



M. Kalyan Ram
Whole Time Director
DIN:02012580

Vivo Bio Tech Ltd
8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate
Road No.1, Banjara Hills, Hyderabad-500034, Telangana
E-mail:investors@vivo.bio.com CIN: L65993TG1987PLC007163

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QTR AND YEAR ENDED 31ST MARCH, 2022

S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED	
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
		Refer Note#2	Un-Audited	Refer Note#2	Audited	Audited
I	Revenue from operations	1,530.54	1,292.02	1,608.13	5,139.10	5,177.52
II	Other Income	-15.26	0	7.87	9.33	7.87
III	Total Income	1,515.28	1,292.02	1,615.99	5,148.33	5,185.38
IV	Expenses					
	a) Increase/(decrease) in stock in trade and WIP	343.08	(12.27)	(342.47)	346.52	(259.86)
	b) Consumption of Raw materials	-	0.00	0.00	0.00	0.00
	c) Purchase of traded goods	299.28	132.65	510.80	797.28	990.56
	d) Employees Cost	280.25	239.36	266.76	942.19	856.99
	e) Depreciation and amortisation	221.06	171.03	167.78	744.65	559.14
	f) Finance Cost	86.61	120.37	132.91	399.33	353.00
	g) Administrative Expenditure	447.53	356.8	772.62	1,471.74	1,833.59
	Total	1,677.80	1,007.94	1,508.40	4,701.70	4,323.41
V	Profit Before Tax & Exceptional Item (III-IV)	(162.52)	284.08	107.60	447.23	861.97
VI	Profit Before Tax	(162.52)	284.08	107.60	447.23	861.97
VII	Tax Expense					
	a. Current Tax	-48.78	43.76	(60.38)	75.85	155.76
	b. Deferred tax	-45.03	103.11	138.22	151.22	157.97
	Total Tax Expense	(93.82)	146.87	77.85	227.06	293.74
	Net Profit After Tax (V-VI)	(68.71)	137.21	29.75	220.16	568.23
VIII	Minority Interest	-	-	-	-	-
IX	Other Comprehensive Income					
	a. Items that will be reclassified to profit or loss (Net of Tax)					
X	Total other Comprehensive Income(VII+VIII+IX)	(68.71)	137.21	29.75	220.16	568.23
XI	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1,426.35	1,420.45	1,341.95	1,426.35	1,341.95
XII	Earnings per equity share:					
	1) Basic	-0.49	0.97	0.22	1.56	4.23
	2) Diluted	-0.49	0.93	0.22	1.56	4.19

Place: Hyderabad
Date: 30th May, 2022

For Vivo Bio Tech Ltd



M. Kalyan Ram
Whole Time Director
DIN:02012580



Vivo Bio Tech Ltd
8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate
Road No.1, Banjara Hills, Hyderabad-500034, Telangana
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2022


Rs. In Lacs

S.No.	Particulars	Standalone		Consolidated	
		31.03.2022	31.03.2021	31.03.2022	31.03.2021
		Audited	Audited	Audited	Audited
I	ASSETS				
	Non-Current Assets				
	Fixed Assets				
	Property, Plant and Equipment	7,818.64	3,735.03	8,154.67	4,071.05
	Capital Work-In-Progress	86.64	32.49	86.64	32.49
	Intangible Assets	1,362.36	1,133.62	1,362.36	1,133.62
	Financial Assets				
	Non-Current Investments	4.00	4.00	-	-
	Long Term Loans and Advances	40.34	4.55	41.71	6.49
	Other Non Current Assets		-		-
	Deferred Tax Asset				
	Total Non-Current Assets	9,311.98	4,909.69	9,645.37	5,243.65
	Current Assets				
	Inventories	981.20	1,327.73	981.20	1,327.73
	Financial Assets				
	Trade Receivables	1,202.43	729.30	1,202.43	729.30
	Cash and cash equivalents	146.63	109.71	171.35	116.54
	Short term loans and advances	298.46	594.83	159.25	475.61
	Other current assets	88.92	59.49	88.92	59.49
	Total Current Assets	2,717.65	2,821.05	2,603.16	2,708.67
	TOTAL ASSETS	12,029.63	7,730.74	12,248.54	7,952.32
II	EQUITY AND LIABILITIES				
	Equity				
	Equity Share Capital	1,426.35	1,341.95	1,426.35	1,341.95
	Other Equity	3,219.17	2,769.59	3,099.27	2,768.09
	Money Received Against Share Warrants	68.96	142.65	68.96	142.65
	Total Equity	4,714.48	4,254.19	4,594.59	4,252.70
	Liabilities				
	Non Current liabilities				
	Financial Liabilities				
	Borrowings	4,787.71	1,242.31	5,007.83	1,464.95
	Long term provisions	55.42	47.83	55.42	47.83
	Defferred Tax Liabilities	154.36	3.14	154.36	3.14
	Total Non Current Liabilities	4,997.50	1,293.28	5,217.62	1,515.92
	Current Liabilities				
	Financial Liabilities				
	Borrowings	1,736.04	1,630.71	1,736.04	1,630.71
	Trade Payable & Other Current Liabilities	231.61	138.83	231.61	138.83
	Provisions	350.01	413.73	468.68	414.17
	Total Current Liabilities	2,317.66	2,183.26	2,436.33	2,183.71
	TOTAL EQUITY & LIABILITIES	12,029.63	7,730.74	12,248.54	7,952.32

Place: Hyderabad
Date: 30th May, 2022

For Vivo Bio Tech Ltd

M. Kalyan Ram
Whole Time Director
DIN:02012580



Vivo Bio Tech Ltd
 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate
 Road No.1, Banjara Hills, Hyderabad-500034, Telangana
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

Vivo Bio Tech Ltd.
 Your Drug Discovery Partner

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2022

Rs. In Lacs

Particulars	As at	As at
	31.03.2022	31.03.2021
	Audited	Audited
A. Cash Flow from Operating Activities:		
Net Profit/ (Loss) before taxation and extraordinary items	447	862
Adjustments for:		
Depreciation	744	559
Amortised Expenses		
Interest expenses	399	353
Operating Profit before Working Capital Changes	1,591	1,774
Working Capital Changes		
Trade and other receivables Including Inventory	105	145
Trade and Other payables	293	137
Cash Generated from Operations	1,989	2,056
Interest paid	399	353
Taxation for the year	227	294
Net Cash from Operating Activities	1,362	1,410
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets	(5,111)	(2,282)
Investment		
Net Cash used in Investing Activities	(5,111)	(2,282)
C. Cash Flow From Financial Activities:		
Proceeds from Equity Shares	240	382
Net Proceeds from Long Term Borrowings	3,545	501
Net Cash used in Financing Activities	3,785	883
Net increase in cash and cash equivalents	37	11
Cash and Cash equivalents as at Beginning of the Year	110	99
Cash and Cash equivalents as at 31.03.2022	147	110

Place: Hyderabad
 Date: 30th May, 2022

For Vivo Bio Tech Ltd

M. Kalyan Ram
 M. Kalyan Ram
 Whole Time Director
 DIN:02012580



Vivo Bio Tech Ltd
 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate
 Road No.1, Banjara Hills, Hyderabad-500034, Telangana
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

Vivo Bio Tech Ltd.
 Your Drug Discovery Partner

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2022


Rs. In Lacs

Particulars	As at	As at
	31.03.2022	31.03.2021
	Audited	Audited
A. Cash Flow from Operating Activities:		
Net Profit/ (Loss) before taxation and extraordinary items	447	862
Adjustments for:		
Depreciation	745	559
Amortised Expenses		
Interest expenses	399	353
Operating Profit before Working Capital Changes	1,591	1,774
Working Capital Changes		
Trade and other receivables Including Inventory	125	153
Trade and Other payables	411	137
Cash Generated from Operations	2,128	2,064
Interest paid	399	353
Taxation for the year	227	294
Net Cash from Operating Activities	1,501	1,418
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets	(5,111)	(2,282)
Investment		-
Net Cash used in Investing Activities	(5,111)	(2,282)
C. Cash Flow From Financial Activities:		
Proceeds from Equity Shares	122	382
Net Proceeds from Long Term Borrowings	3,543	496
Net Cash used in Financing Activities	3,665	878
Net increase in cash and cash equivalents	55	14
Cash and Cash equivalents as at Beginning of the Year	117	103
Cash and Cash equivalents as at 31.03.2022	171	117

Place: Hyderabad
 Date: 30th May, 2022

For Vivo Bio Tech Ltd

M. Kalyan Ram
 Whole Time Director
 DIN:02012580




Notes

1. The above Audited Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30th May, 2022.
2. The figures for the quarter ended 31st March 2022 and 31st March 2021 are the balancing figure between the audited figures of the full financial year and the published year-to-date figures upto the 3rd quarter of respective financial years which were subject to Limited Review by the Statutory Auditor of the Company.
3. The Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakanti Consulting Services Private Limited).
5. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
6. The Company has allotted 6,55,000 equity shares to the promoter group pursuant to conversion of warrants during the financial year 2021-22.
7. The Company had allotted 1,30,000 and 59,000 equity shares on 06th May, 2021 and 02nd February, 2022 respectively to the eligible employees of the Company upon conversion of Stock Options granted pursuant to the Employees Stock Option Scheme during the financial year 2021-22.
8. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

Place: Hyderabad

Date: 30th May, 2022

For Vivo Bio Tech Limited



Kalyan Ram Mangipudi

Kalyan Ram Mangipudi
Whole Time Director
DIN: 02012580

Date: 30th May, 2022

To
The Manager
Dept of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001

Dear Sir/Madam,

Subject : Declaration for unmodified opinion pursuant to Regulation 33 (3) (d) of the SEBI (LODR) Regulations, 2015

Scrip Code : 511509

We hereby declare that the Statutory Auditors of the Company i.e., M/s. P C N & Associates, Chartered Accountants (Firm Reg No. 016016S) have issued Audit Reports with unmodified opinion on the Audited Standalone & Consolidated financial results of the Company for the year ended on 31st March, 2022.

The above declaration is issued in compliance with Regulation 33 (3) (d) of the SEBI (LODR) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD /56/2016 dated 27th May, 2016.

This is for your information and records.


Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited



Kalyan Ram Mangipudi
Whole Time Director
DIN: 02012580





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

INDEPENDENT AUDITOR'S REPORT

TO
THE BOARD OF DIRECTORS OF
M/s. VIVO BIO TECH LIMITED

Report on the audit of the Standalone Financial Results

Opinion:


We have audited the accompanying standalone quarterly financial results of M/s. Vivo Bio Tech Limited for the quarter ended 31st March, 2022 and the year to date results for the period from 01-04-2021 TO 31-03-2022, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31st March, 2022 as well as the year to date results for the period from 01-04-2021 to 31-03-2022.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.


Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The Financial Results include the results for the quarter ended 31st March 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For P C N & Associates
Chartered Accountants
Firm's Registration No: 016016S

M. Mohana Saradhi
Partner
Membership No. 244686
UDIN: 22244686AJXZUW4725



Place: Hyderabad
Date: 30.05.2022.



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

INDEPENDENT AUDITOR'S REPORT

THE BOARD OF DIRECTORS OF
M/s. VIVO BIO TECH LIMITED

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of -M/s. VIVO BIO TECH LIMITED ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), for the quarter ended 31st March 2022 and for the period from 01-04-2021 to 31-03-2022 ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the report of the other auditor on separate financial statements/ financial information of subsidiary, the aforesaid consolidated financial results:

a. includes the results of the following entities:

- I. Vivo Bio Labs Private Limited
- II. Vivo Bio Discovery Services Private Limited
- III. Surlogic Life Consultancy Private Limited
- IV. Vivo Bio Consulting Services Private Limited (Formerly known as Donakanti Consultancy Services Private Limited)

b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and

c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net profit and other comprehensive income) and other financial information of the Group for the quarter ended 31st March 2022 and for the period from 01-04-2021 to 31-03-2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com


Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.


Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

financial results represent the underlying transactions and events in a manner that achieves fair presentation.


- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

The consolidated Financial Results include the audited Financial Results of four subsidiaries, whose Financial Statements before eliminations reflect Group's share of total assets of Rs.383.12/- Lakhs as at 31st March 2022, Group's share of total revenue before elimination of Rs. (Nil) and Group's share of total net profit/(loss) after tax of Rs.(0.78) Lakhs for the quarter ended 31st March 2022 and Group's share of total revenue of Rs. 0.62/- Lakhs and Group's share of total net profit/(loss) after tax of Rs. (0.16) Lakhs for the period from 01-04-2021 to 31-03-2022 respectively, as considered in the consolidated Financial Results, which have been audited by their respective independent auditor. The independent auditors' reports on financial statements of this entity have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditor and the procedures performed by us as stated in paragraph above.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

The Financial Results include the results for the quarter ended 31st March 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For P C N & Associates
Chartered Accountants

Firm's Registration No: 016016S

M. Mohana Saradhi

Partner

Membership No. 244686

UDIN: 22244686AJXZWY2527



Place: Hyderabad

Date: 30.05.2022.

Date: 30th May, 2022

To
The Manager
Dept of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001

Dear Sir/Madam,

Subject : Declaration for unmodified opinion pursuant to Regulation 33 (3) (d) of the SEBI (LODR) Regulations, 2015
Scrip Code : 511509

We hereby declare that the Statutory Auditors of the Company i.e., M/s. P C N & Associates, Chartered Accountants (Firm Reg No. 016016S) have issued Audit Reports with unmodified opinion on the Audited Standalone & Consolidated financial results of the Company for the year ended on 31st March, 2022.

The above declaration is issued in compliance with Regulation 33 (3) (d) of the SEBI (LODR) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD /56/2016 dated 27th May, 2016.

This is for your information and records.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited



Kalyan Ram Mangipudi
Whole Time Director
DIN: 02012580

